Ambrx
Rahel Schnellmann, PhD, is a skilled scientist with extensive experience in biochemistry and molecular biology, holding a Doctor of Philosophy degree from the Friedrich Miescher Institute for Biomedical Research. Currently serving as Scientist II at Ambrx, a Johnson and Johnson Company, since October 2023, Schnellmann focuses on ADC process development, leading media development efforts, managing direct reports, and contributing to technology transfer. Prior roles include upstream process development at Cellics Therapeutics, where Schnellmann worked on cell culture and bioreactor systems, and as a Scientist in Cancer Immunology at Fate Therapeutics, leading projects in biomarker discovery and cell therapy. Previous experience includes a postdoctoral position at Johns Hopkins Institute for NanoBioTechnology focusing on regenerative medicine and tumor metastasis investigation during a PhD at Friedrich Miescher Institute, complemented by additional training experiences at Cleveland Clinic and Imperial College London.
This person is not in any teams
Ambrx
Ambrx, Inc. is a biopharmaceutical company with a mission to deliver breakthrough protein therapeutics. Ambrx is based on a fundamental advance in protein biosynthesis that enables the company to genetically engineer proteins with new amino acid building blocks beyond the common twenty, enabling the biosynthesis of proteins with new physical, chemical and pharmacological properties.